$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What is the drug profile and indications of filgotinib?
2026-02-01 22:25:32
Check Details
Detailed instructions for Trientine
2026-02-01 22:25:32
Check Details
Mirikizumab in Crohn's disease
2026-02-01 22:25:32
Check Details
The application prospects and current situation of Lorlatinib in the treatment of ALK-positive non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Remibrutinib-RHAPSIDO is a medicine that treats what
2026-02-01 22:25:32
Check Details
Whether selumetinib/coceyu has been approved by the FDA
2026-02-01 22:25:32
Check Details
What are the common adverse reactions of Lorlatinib/Lorlatinib (Borina)?
2026-02-01 22:25:32
Check Details
Recommendations on the best medication time and dose adjustment for Platinib (Pujihua)
2026-02-01 22:25:32
Check Details
Precautions and effects of combined treatment with capmatinib (Touradida) and radiotherapy
2026-02-01 22:25:32
Check Details
Which lung cancer patients is Sutolaxib (AMG 510) suitable for and prediction of drug effects?
2026-02-01 22:25:32
Check Details
Estimated launch time and market prospects of Krazati in the country
2026-02-01 22:25:32
Check Details
Analysis of the mechanism of action of Pimitespib and its advantages in targeted therapy
2026-02-01 22:25:32
Check Details
1
2
...
2181
2182
2183
2184
2185
2186
2187
...
10240
10241
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Momelotinib for Myelofibrosis: Spleen Response, Symptom Improvement and Efficacy Monitoring
2
Pirtobrutinib and Risks of Atrial Fibrillation and Bleeding: Mechanism, Data Interpretation and Monitoring
3
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
4
Ixazomib (Ninlaro) Dosing Schedule, Missed Dose Management and Cycle Planning in 28‑Day Regimen
5
Ponatinib in the PACE Phase II Trial: Response Data in Resistant CML and Ph+ ALL
6
Selumetinib for NF1-Related Plexiform Neurofibromas: Time to Response and Response Assessment
7
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
8
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
9
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
10
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
11
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
12
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks